SYK and rheumatoid arthritis: Interestingly, SYK inhibitors were investigated for autoimmune diseases with major B-cell involvement, including rheumatoid arthritis (214), and the first FDA approval of a SYK inhibitor, fostamatinib was granted for treatment of immune thrombocytopenia (ITP) (215).